P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against P2RY12 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

• 2025-03-30Results posted on the registry: University of Florida, Ticagrelor monotherapy + Ticagrelor plus aspirin (NCT04484259)
• 2025-03-12Phase 3 first posted: University of Sao Paulo, Clopidogrel (NCT06872541)
• 2025-03-03Phase 3 first posted: Sichuan Provincial People's Hospital, The ticagrelor + The Clopidogrel (NCT06853535)
• 2025-02-18Results posted on the registry: Feng Gao, endovascular recanalization (NCT04864691)
• 2025-01-31Results posted on the registry: University of Calgary, Tenecteplase + Antiplatelet treatment (NCT02398656)
• 2024-12-30Results posted on the registry: Matthew Neal MD, theraputic heparin + prophylactic heparin (NCT04505774)
• 2024-12-27Also stopped (terminated): National Hospital Organization Osaka National Hospital, Oral Anticoagulant + Antiplatelet Drug (NCT03062319)
• 2024-12-27Results posted on the registry: HonorHealth Research Institute, Dual Antiplatelet (DAPT) Therapy (NCT03606642)
• 2024-12-27Also stopped (terminated): HonorHealth Research Institute, Dual Antiplatelet (DAPT) Therapy (NCT03606642)
• 2024-12-19Phase 3 first posted: National Institute of Cardiovascular Diseases, Pakistan, Apixaban 2.5 MG PO BID + Control (Standard treatment) (NCT06742567)
• 2024-10-17Results posted on the registry: Merck Sharp & Dohme LLC, MK-2060 (NCT05335005)
• 2024-10-04Results posted on the registry: KU Leuven, Tenecteplase + Clopidogrel (NCT02777580)
• 2024-09-26Also stopped (suspended): St. Joseph's Hospital and Medical Center, Phoenix, a drug against P2RY12 (NCT02513914)
• 2024-09-19Phase 3 first posted: Kafrelsheikh University, Ticagrelor 90 MG + Cilostazol 100 MG (NCT06591377)
• 2024-09-19Phase 3 first posted: Kafrelsheikh University, Ticagrelor 90 MG + Clopidogrel (NCT06591338)
• 2024-09-19Phase 3 first posted: Capital Medical University, Tirofiban Hydrochloride + Standard medical treatment (SMT) (NCT06587347)
• 2024-09-19Phase 3 first posted: Kafrelsheikh University, Ticagrelor 90 MG + Cilostazol 100 MG (NCT06591390)
• 2024-09-19Phase 3 first posted: Kafrelsheikh University, Ticagrelor 90 MG + Clopidogrel (NCT06591312)
• 2024-09-19Phase 3 first posted: Kafrelsheikh University, Cilostazol 100 MG + Clopidogrel (NCT06591351)
• 2024-09-19Phase 3 first posted: Kafrelsheikh University, Cilostazol 100 MG + Clopidogrel 75mg (NCT06591299)
• 2024-08-29Phase 3 first posted: Jiangsu vcare pharmaceutical technology co., LTD, Vicagrel + Clopidogrel (NCT06577519)
• 2024-08-20Also stopped (terminated): University Hospital, Strasbourg, France, No oral anticoagulation + Oral anticoagulation with vitamin K antagonists (NCT02886962)
• 2024-08-20Phase 3 first posted: Kafrelsheikh University, Ticagrelor 90 MG + Cilostazol 100 MG (NCT06561867)
• 2024-05-16Phase 3 first posted: Beijing Tiantan Hospital, rhTNK-tPA + Control group (Aspirin combined with clopidogrel) (NCT06414499)
• 2024-05-06Results posted on the registry: University of Maryland, Baltimore, Clopidogrel + Ticagrelor (NCT03161678)

What is not public

• Internal portfolio and board discussions
• Unpublished trial data and interim analyses
• Terms of any partner or licence decision